Sunshine Biopharma Inc.

Sunshine Biopharma Inc. is a U.S.-based pharmaceutical company organized around generic prescription drugs, over-the-counter supplements, and proprietary drug development. Through its Canadian subsidiaries, it markets and distributes a broad portfolio of medicines in Canada while also advancing early-stage oncology and antiviral candidates.

−16,2 %

33,8 %

−16,5 %

+4,1 %

4.17

2.08

— Sunshine Biopharma Inc.
%
Generic prescription pharmaceuticals80% Branded and unbranded generic medicines sold in Canada through Nora Pharma.
Distribution-based pharmaceutical products10% Products sold under distribution agreements where the company acts as distributor and earns a sales share or margin.
OTC supplements5% Health supplements and nutraceutical products sold through Sunshine Biopharma Canada.
Proprietary drug development5% Early-stage internal pipeline assets including K1.1 and SBFM-PL4.

The company sells primarily into the Canadian pharmaceutical supply chain, with pharmacies and other drug purchasers...

  • Canadian pharmaciesprimary

    Buy generic prescription drugs for dispensing to patients and rely on supply continuity and regulatory approval.

  • Pharmaceutical distribution partnersprimary

    Provide product rights or supply arrangements that the company commercializes in Canada.

  • Retail and pharmacy supplement buyerssecondary

    Purchase OTC products such as Essential•9, Calcium-Vitamin D, L-Citrulline, and Taurine.

  • Healthcare providers and patients in target indicationsemerging

    Represent the eventual end market for proprietary oncology and antiviral candidates.

Sunshine Biopharma is headquartered in the United States but its commercial footprint is centered in Canada through...

  • •Headquartered in the United States
  • •Commercial operations concentrated in Canada
  • •Nora Pharma sells generic drugs under Canadian approvals
  • •Sunshine Biopharma Canada develops and sells OTC products
  • •Global licensing and patent rights support broader expansion

The company’s strategy is to expand its Canadian generic-drug portfolio through in-licensing, cross-licensing, and...

01
Expand Canadian product breadthshort-term

A wider portfolio improves pharmacy access and strengthens the company’s position with buyers.

02
Build proprietary pipeline valuemedium-term

Internal drug candidates can create differentiated long-term upside beyond generic distribution.

03
Increase commercialization efficiencyshort-term

Better sourcing and product mix can improve the economics of the distributor model.

The business depends on regulatory approvals, product dossier execution, and third-party supply arrangements, which can...

high

Regulatory approval and dossier execution risk

Products must be approved by Health Canada before commercialization, which can delay launches.

Scope
Canadian generic portfolio and new product launches
Materiality
high
high

Third-party supply and licensing dependence

Many products are sourced through in-licenses, cross-licenses, or distribution agreements.

Scope
Generic prescription and distribution-based products
Materiality
high
high

Intangible asset impairment

Product licenses may not be commercializable, requiring write-downs.

Scope
Licensed product dossiers and acquired rights
Materiality
high
high

Financing dependence

R&D and expansion can require external funding if operating cash is insufficient.

Scope
Corporate liquidity and growth plans
Materiality
high
medium

Pipeline development failure

K1.1 and SBFM-PL4 are early-stage and may not reach commercialization.

Scope
Proprietary R&D
Materiality
medium
Revenue recognition on distribution agreements
Can change gross revenue, net revenue, and margin presentation
Intangible asset impairment
Can materially reduce earnings and asset carrying values
Inventory and cost of finished products
Affects gross margin and quarter-to-quarter comparability
Capitalized product rights and licenses
Can influence amortization and impairment charges

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Regen BioPharma Inc

RGBP · Pharmaceutical Preparations

SUTRO BIOPHARMA, INC.

STRO · Biological Products, (No Diagnostic Substances)

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

NATURES SUNSHINE PRODUCTS INC

NATR · Pharmaceutical Preparations

: 29/04/2026